Author of

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17626

    +

    P2.03a-070 - A Feasibility Study of Adjuvant Chemotherapy with Modified Weekly Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC (ID 4989)

    14:30 - 14:30  |  Author(s): H. Marushima
    • Abstract

    Background:
    Albumin-bound paclitaxel (nab-paclitaxel) has been demonstrated to improve outcomes with lesser neuropathy compared to that with paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). However, the feasibility of adjuvant chemotherapy setting is still uncertain. This phase II trial assessed the feasibility of adjuvant chemotherapy with nab-paclitaxel and carboplatin in patients who underwent complete resection of pathological stage IB/II/IIIA NSCLC (UMIN000011225).
    
    Methods:
    Patients with completely resected pathological stage IB/II/IIIA NSCLC were recruited from July, 2013. Patients were administered adjuvant chemotherapy with 4 cycles of carboplatin (AUC 5) on day 1 and nab-paclitaxel (100 mg/m2) on days 1 and 8 every 3 weeks. The primary endpoint was the completion of 3 cycles of chemotherapy. The sample size was set at 30 patients, and the treatment was considered feasible if the 80% CI of the completion rate of 3 cycles of chemotherapy was ⩾60%, α=0.05 and β=0.2.
    
    Results:
    The study enrolled 30 patients including 2 pilot patients. The median relative dose intensities of modified weekly carboplatin and nab-paclitaxel were 80% and 70%, respectively. First two pilot patients were required dose reduction in conventional weekly carboplatin (AUC5) on day1 and nab-paclitaxel (100 mg/m2) on days 1, 8 and 15 every 3 weeks, therefore we modified this setting. Among the treated patients, grade 3 adverse event listed neutropenia (60%) and thrombocytopenia (10%). Dose delays were observed in 20% of patients owing to neutropenia (85%). In this interim result analysis, all 10 patients completed 3 cycles of chemotherapy. Conversely, neuropathy did not develop in any patients. Neither febrile neutropenia nor treatment-related mortality was observed in this study.
    
    Conclusion:
    Based on the results, modified adjuvant chemotherapy with weekly nab-paclitaxel and carboplatin is feasible, with acceptable hematologic and non-hematologic toxicity, in patients who underwent complete resection of pathological stage IB/II/IIIA NSCLC.